Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Arani Vivekanantham


NIHR Academic Clinical Fellow in Rheumatology

Academic rheumatology trainee interested in using big data to generate reliable evidence to improve the care and lives of people living with inflammatory arthritis.

Arani is an NIHR Academic Clinical Fellow and Specialist Registrar in Rheumatology at Oxford. She studied undergraduate medicine at Keele University Medical School, where she also undertook an intercalated Master of Philosophy (MPhil) at the Arthritis Research UK Primary Care Centre. Following this Arani has followed the NIHR Integrated Clinical Academic Training pathway to date. She completed the Academic Foundation Programme at the University of Warwick and University Hospitals Coventry and Warwickshire. She then became an NIHR Academic Clinical Fellow in Rheumatology at the University of Manchester and Manchester University NHS Foundation Trust, where she completed her Core Medical Training. Following this she came to Oxford to start her specialist training in Rheumatology as an NIHR Academic Clinical Fellow at the University of Oxford and Oxford University Hospitals. 

Arani has a research interest in using routinely collected healthcare data to answer clinically relevant questions to improve the care and lives for people living with inflammatory arthritis. She is working with Professor Dani Prieto Alhambra and Prof Laura Coates within NDORMS. Her current research work aims to understand which people with psoriasis develop psoriatic arthritis with the aim to develop a prediction model to support early diagnosis and treatment of people with psoriatic arthritis. She also aims to look at the safety of the first line treatments used in people with psoriatic arthritis and the impact that other underlying co-morbidities may have in development of side-effects from these. 

Recent publications

More publications